Leading Independent Proxy Advisory Firm ISS Recommends Liberty Health Science Shareholders Vote "FOR" Proposed Acquisition by Ayr

TORONTO, Feb. 11, 2021 /CNW/ - Liberty Health Sciences Inc. (CSE: LHS) (OTCQX: LHSIF) www.libertyhealthsciences.com ("Liberty" or the "Company"), a provider of high-quality cannabis, today announced that leading independent proxy advisory firm, Institutional Shareholder Services ("ISS"), recommends that Liberty shareholders vote "FOR" the shareholder proposal relating to Ayr Strategies Inc.'s (CSE:AYR.A, OTCQX: AYRWF) ("Ayr") proposed acquisition of Liberty Health Sciences.

In its February 9, 2021 report, ISS stated: Vote "FOR" this proposal based on a review of the terms of the transaction, in particular, the significant premium, the favorable market reaction, and the reasonable strategic rationale.

"We are pleased that ISS shares our belief that the transaction we have proposed is good for Liberty shareholders and supports the Liberty Board's recommendation to vote "FOR" the proposed acquisition by Ayr," said George Gremse, Interim Chief Executive Officer and Director of Liberty. "Together, Ayr and Liberty will be a competitive force in Florida."

On December 22, 2020, Ayr announced the proposed acquisition of Liberty in a stock-for-stock combination. Liberty shareholders will receive 0.03683 Ayr shares for each Liberty share held, equating to 94% premium on the day of the announcement. Since then, the value of the transaction has increased by an additional 62% to C$1.71 per share based on the closing price of Ayr's shares on February 10, 2021.

The Liberty acquisition is subject to customary closing conditions, regulatory approvals, including HSR review, Liberty shareholder approval and court approval of the Plan of Arrangement. A Shareholder meeting and vote is scheduled for February 23, 2021. The Management Information Circular, including Proxy and voting instructions, have been sent to Liberty shareholders and can be found on SEDAR. Shareholders holding approximately 29% of Liberty's common shares have agreed to support and vote in favor of the proposed transaction.

Shareholders are encouraged to vote their form of proxy or voting instruction form "FOR" the Plan of Arrangement with Ayr Strategies. In order to ensure that votes are counted at the Special Meeting of Securityholders, proxy or voting instructions need to be received prior to the deadline of 10:00 a.m. EST on February 19, 2021.

Please call Carson Proxy with any questions or need for assistance voting at: 800-530-5189 (toll-free) in North America, or 416-751-2066 (collect) outside North America, or by email at: info@carsonproxy.com.

About Liberty Health Sciences Inc.
Liberty is the cannabis provider committed to providing a high-quality cannabis experience based on our genuine care for all cannabis users and a focus on operational excellence from seed to sale. For more information, please visit: www.libertyhealthsciences.com.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS: This press release contains certain forward-looking statements within the meaning of applicable securities laws. Any statements that are contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements are often identified by terms such as "may", "should", "anticipate", "expect", "believe", "plan", "intend" or the negative of these terms and similar expressions. Forward-looking statements in this news release include, but are not limited to, expectations related to the Company's production capabilities, expectations concerning the receipt of all necessary approvals from the Florida Department of Health, expectations concerning the opening of new dispensaries and the expansion of its greenhouse space, and the Company's future expansion and growth strategies. Forward-looking statements necessarily involve known and unknown risks, including, without limitation, risks associated with general economic conditions; adverse industry events; marketing costs; loss of markets; future legislative and regulatory developments involving medical marijuana; inability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favorable terms; the medical marijuana industry in the United States generally, income tax and regulatory matters; the ability of Liberty to implement its business strategies; competition; crop failure; currency and interest rate fluctuations and other risks. Readers are cautioned that the foregoing list is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking statements as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement.

SOURCE Liberty Health Sciences Inc.

For further information: Media Contacts: Dwain Schenck, (203) 223-5230, dwain@schenckstrategies.com; George Gremse, Interim Chief Executive Officer, (833) 254-4877, GGremse@libertyhealthsciences.com